Oppenheimer began coverage on shares of Gamida Cell (NASDAQ:GMDA) in a research note released on Wednesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $15.00 price objective on the stock.
GMDA has been the subject of a number of other research reports. Royal Bank of Canada initiated coverage on Gamida Cell in a research report on Tuesday. They issued an outperform rating and a $20.00 price objective for the company. BMO Capital Markets initiated coverage on Gamida Cell in a research report on Wednesday. They issued a buy rating and a $19.00 price objective for the company.
Gamida Cell stock opened at $14.90 on Wednesday. Gamida Cell has a 1-year low of $7.99 and a 1-year high of $15.39.
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase 3 clinical trials for use as a curative stem cell graft for patients in hematopoietic stem cell transplant.
Featured Story: Intrinsic Value
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.